Altimmune (ALT1) Stock Price & Analysis
ALT1 Stock Chart & Stats
- Day’s Range
- MXN 38.00 - MXN 50.00
- 52-Week Range
- MXN 1.00 - MXN 111.00
- Previous Close
- MXN 42.25
- Volume
- 0
- Average Volume (3M)
- 317
- Market Cap
- MXN 7.37B
- Enterprise Value
- MXN 273.45M
- Total Cash (Recent Filing)
- MXN 326.32M
- Total Debt (Recent Filing)
- MXN 35.75M
- Price to Earnings (P/E)
- ―
- Beta
- -0.11
- Next Earnings
- Nov 10, 2026 (Est.)
- EPS Estimate
- -2.45
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Late-stage Clinical Progress
Starting a global Phase III program materially advances pemvidutide toward potential approval in MASH. The planned scale and defined readout create a clearer development path, while positive AUD Phase II results and completed ALD enrollment broaden the pipeline’s clinical opportunity.
Strong Liquidity Runway
A substantial cash balance with runway through the PERFORMA 52-week readout reduces near-term financing pressure for the principal MASH program. This supports uninterrupted execution across a long clinical timeline and gives management time to pursue partnerships or other funding options.
Low Financial Leverage
Low leverage and a materially larger equity and asset base provide greater financial flexibility than a highly indebted development-stage peer. This strengthens the company’s ability to fund clinical work and negotiate future financing without relying entirely on additional debt.
Bears Say
Persistent Cash-burning Losses
Altimmune remains pre-commercial, with negligible product revenue and losses far exceeding current operating inflows. Sustained annual cash burn means its research and clinical programs depend on external capital, limiting financial self-sufficiency and creating ongoing dilution or funding risk.
AUD Funding Gap
The company’s stated runway prioritizes PERFORMA but excludes a potential pivotal AUD study. Advancing that opportunity therefore depends on royalties, debt, or partnerships that are not guaranteed, creating a meaningful capital and execution constraint around pipeline expansion.
GI Tolerability Risk
Gastrointestinal discontinuations could limit treatment persistence or complicate dosing in later-stage development if the pattern persists. Further analysis is required, so tolerability remains a key execution variable that could affect trial outcomes, regulatory discussions, and eventual adoption.
Altimmune News
Altimmune’s Phase 3 MASH Trial Puts Pemvidutide in the Spotlight for Investors
Altimmune ($ALT) announced an update on their ongoing clinical study. Altimmune, Inc. has launched a major Phase 3 study called “A Phase 3, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to
ALT1 FAQ
What was Altimmune’s price range in the past 12 months?
What is Altimmune’s market cap?
When is Altimmune’s upcoming earnings report date?
How were Altimmune’s earnings last quarter?
Is Altimmune overvalued?
Does Altimmune pay dividends?
What is Altimmune’s EPS estimate?
How many shares outstanding does Altimmune have?
What happened to Altimmune’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Altimmune?
What is the TipRanks Smart Score and how is it calculated?
Altimmune Stock Smart Score
Company Description
Altimmune
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jerome Benedict Durso
- Employees
- 57
- Website
- altimmune.com
- Address
- 910 Clopper Road, Gaithersburg, MD, 20878, US
Altimmune (ALT1) Earnings & Revenues
ALT1 Earnings Call
Earnings Call SentimentPositive
The call conveyed substantial clinical and operational momentum: initiation of a global Phase III in MASH, robust positive Phase II AUD data that met multiple registrational endpoints (including objective biomarker improvements and 9.1% weight loss), completed enrollment in ALD, and a strengthened balance sheet ($519M cash). Key positives notably outweigh near‑term risks, though important caveats remain — including higher operating expenses, GI-related tolerability signals under further review, a competitive MASH enrollment landscape, and the need to secure non-dilutive funding for a potential AUD Phase III (not covered by the current runway). Several pivotal readouts (RESTORE H2 2027, PERFORMA 52‑week in 2029) and regulatory engagements are upcoming and will be determinative for long-term value.
View all MX:ALT1 earnings summariesALT1 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 3 | 4 | 15 |
| Technical Analysis | 3 | 3 | 4 |
| Moving Averages | 0 | 1 | 11 |
